Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring

One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following allogeneic hematopoietic stem cell transplantation (HSCT). Building on the proven performance of the existing assay for chimerism monitoring, this assay features an innovative assay design that reduces the risk of errors associated with complex testing workflows while improving laboratory efficiency and ease of use. 

"The launch of One Lambda Devyser Chimerism Plus is an important step in our collaboration with Thermo Fisher Scientific," said Jan Wahlström, CEO of Devyser. "We are happy to provide laboratories with a robust solution for chimerism monitoring while expanding our commercial opportunities in the market." 

This launch builds on the established collaboration between Devyser and Thermo Fisher Scientific and expands the company's offering through Thermo Fisher Scientific's established commercial network. 

"This launch expands our presence in the market and supports our growth ambitions in the coming year," added Michael Ulhin, CSO, Devyser.
 
"We are pleased to continue collaborating with Devyser to support laboratories performing chimerism analysis," said Tina Liedtky, president of the transplant diagnostics business at Thermo Fisher Scientific. "The launch of One Lambda Devyser Chimerism Plus reflects our shared commitment to providing laboratories with solutions that help streamline post-transplant monitoring workflows while delivering the reliable results clinicians need to support patient care.”
 
Disclaimer: One Lambda Devyser Chimerism Plus is for research use only (RUO). Not for use in diagnostic procedures.